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Most cases of early onset DYT1 dystonia in humans are caused by a GAG deletion in the TOR1A gene leading to loss of a
glutamic acid (ΔE) in the torsinA protein, which underlies a movement disorder associated with neuronal dysfunction without
apparent neurodegeneration. Mutation/deletion of the gene (Dst) encoding dystonin in mice results in a dystonic movement
disorder termed dystonia musculorum, which resembles aspects of dystonia in humans. While torsinA and dystonin proteins do
not share modular domain architecture, they participate in a similar function by modulating a structural link between the nuclear
envelope and the cytoskeleton in neuronal cells. We suggest that through a shared interaction with the nuclear envelope protein
nesprin-3α, torsinA and the neuronal dystonin-a2 isoform comprise a bridge complex between the outer nuclear membrane and
the cytoskeleton, which is critical for some aspects of neuronal development and function. Elucidation of the overlapping roles
of torsinA and dystonin-a2 in nuclear/endoplasmic reticulum dynamics should provide insights into the cellular mechanisms
underlying the dystonic phenotype.
1.Introduction
1.1.HumanDYT1Dystonia. Dystoniaisthethirdmostcom-
mon movement disorder in humans, following essential
tremor and Parkinson’s disease. Dystonia is characterized by
involuntary sustained muscle contractions that lead to twist-
ing movements and abnormal postures [1]a n dc o m p r i s e
a heterogeneous set of clinical syndromes (for review see
[2, 3]). Dystonias are generally classiﬁed on the basis of the
bodily distribution of symptoms (focal, segmental, or gener-
alized), age of disease onset (early or late), and etiology (pri-
maryorsecondary).Dystoniasareclassiﬁedasprimarywhen
the symptoms develop spontaneously in the absence of any
apparent cause or associated disease and as secondary when
symptoms result from other disease states, for example Par-
kinson’s disease or brain injury. Dystonia can be caused by
dysfunction in many regions of the human brain, usually
without detectable neurodegeneration. However, in a few
hereditary dystonia conditions and secondary cases of dys-
tonia, neurodegeneration may be involved.
Many primary dystonias have a hereditary component,
andoncetheabnormalmovementsappeartheydonotremit.
Twenty diﬀerent genes have been implicated in various types
of dystonia, many of which are inherited as autosomal dom-
inant traits with reduced penetrance [4, 5]. Therefore, the
identiﬁcation of common molecular pathways that underlie
multiple dystonia subtypes would improve our ability to
develop new treatment strategies with wide therapeutic
applications. Among the known human dystonia genes, the
TOR1Agene,encoding thetorsinA protein, is responsible for
early-onset, torsion dystonia (DYT1) and has been the most
studied type of dystonia [6]. Historically, DYT1 dystonia was2 International Journal of Cell Biology
referred to as dystonia musculorum deformansand thought to
be inherited as an autosomal recessive condition [7, 8].
DYT1 is a severe form of hereditary, generalized dystonia
[9]. Most cases are now known to be caused by a dominantly
inherited in-frame GAG deletion in the TOR1A gene, with
only a few other isolated mutations in this gene associated
withadystonicphenotype[10–12].TheGAGdeletionresults
in loss of a glutamic acid residue in the protein product,
referred to as torsinAΔE. DYT1 patients are all heterozygous
gene carriers, with no homozygotes harboring the mutation
identiﬁed in humans to date.
1.2. TorsinA Findings. Since the discovery of the TOR1A
gene [6], a number of cellular processes have been associated
with torsinA, albeit the speciﬁc molecular mechanism
through which mutated torsinA leads to DYT1 dystonia
remains unclear. TorsinA is predominantly localized in the
contiguous lumen of the endoplasmic reticulum (ER) and
the nuclear envelope (NE). However, when the mutant form
of torsinA, torsinAΔE, is overexpressed, it concentrates in
the perinuclear space of the NE, forming inclusions in both
neuronal and nonneuronal cells [13–16]. In the few studies
published on neuropathology in DYT1 brains, abnormali-
ties in torsinA localization or signs of inﬂammation/neuro-
degeneration have not been reported [17, 18]. In a small
sample set, dopaminergic cell bodies in the substantia nigra
appeared to be enlarged in DYT1 patients compared to
normal individuals [19]. In one report, pathological abnor-
malities were described in brains of DYT1 patients, included
ubiquitin and torsinA-positive inclusions in neurons in the
brainstem, ubiquitin-positive inclusions in pigmented neu-
rons in the substantia nigra and locus coeruleus, as well as
elevated levels of tau, a protein associated with microtubules
(MTs) [20]. Similar inclusions have been observed in some
of the DYT1 mouse models generated by transgenic over-
expression of human torsinAΔE [21–23].
In mouse models of DYT1 dystonia, including homozy-
gousknock-outoftorsinAandknock-inoftorsinAΔE,mark-
ed morphological changes have been found in the NE of
neurons [24]. These ﬁndings suggest that neurons are espe-
cially dependent on the function of torsinA in deﬁning nu-
clear structure, which, in turn, may aﬀect movement of the
nucleus in relationship to the cytoskeleton during neuronal
migration in developmental phases. TorsinA interacts with
proteins that span the inner nuclear membrane (INM), spe-
ciﬁcally lamina-associated polypeptide 1 (LAP1) [25]a n d
Sad1 and UNC84 domain containing 1 (SUN1) [26], as well
as proteins in the outer nuclear membrane (ONM), such as
the nesprins (nuclear envelope spectrin repeat) [27]. LAP1
is a type II membrane protein consisting of three variants,
LAP1A, 1B, 1C, which play a crucial role in providing at-
tachment of lamins to the INM [28]. LAP1 depletion causes
similar NE abnormalities to those observed in torsinA-null
cells [29]. Furthermore, the absence of SUN1 results in
movement of torsinA and torsinAΔE away from the NE into
the ER. In contrast, LAP1 is not required for torsinAΔE
localization to the NE. SUN proteins have a nuclear domain
that mediates interaction with lamins and an NE lumenal
domainthatinteractswithnesprinproteins,therebyforming
the “linker of nucleoskeleton and cytoskeleton” (LINC)
complex [30–33]. Nesprin proteins are exclusively ONM
cytoskeletal linkers mediating interactions of the nucleus
with various cytoskeletal structures, such as actin ﬁlaments
(AFs), intermediate ﬁlaments (IFs), and MTs, as well as
associated motor proteins, such as kinesin-1/2, dynein, and
dynactin [34]. Therefore, torsinA and its NE interacting
proteins may have a role in modulating the link between the
NEandthecytoskeleton,enablingthenucleustonegotiateits
position within the cell during polarization, migration, and
diﬀerentiation.
1.3. Murine Dystonia Musculorum (dt). Mutations in the
dystonin (Dst) gene in mice result in a movement disorder
phenotypically resembling some aspects of early-onset tor-
sion dystonia in humans. These mice were therefore termed
dt [35, 36]. While heterozygous dt mice appear to be normal
throughout life, homozygous dt mice exhibit an early-onset
phenotype. Mice are asymptomatic at birth, but by postnatal
days 10–12 they begin to exhibit signs of twitching, writhing,
and uncoordinated movements. The dt mice are typically
characterizedas havingasensory neuropathy withassociated
neurodegeneration, although motor neuron abnormalities
and some brain involvement have recently been identiﬁed
[37].
1.4. Parallels between Human DYT1 and Murine dt Dystonias.
Although there are many diﬀerences between human DYT1
dystonia, a dominantly inherited brain disorder with no
marked neuropathology, and murine dt dystonia, a reces-
sively inherited disorder primarily involving neurodegener-
ation in the peripheral nervous system, these forms of dys-
tonia share common elements at the level of cellular dys-
function. A comparison of these disorders was initially con-
founded by the fact that aberrations in function of the
humanhomologueoftheDst mousegeneareassociatedwith
skin blistering, as well as neuropathologies, and not with hu-
man dystonia [38–40].
Surprisingly, recent molecular and cellular studies on the
functions of dystonin and torsinA have provided interesting
molecular parallels between the potential roles of these pro-
teins in interactions between NE/ER and the cytoskeleton.
Both torsinA and the dystonin-a2 neuronal isoform have
been reported to interact with nesprin-3α [27, 41]l o c a t e d
in the ONM of the NE [42]. Nesprin-3α interacts with the
multifunctional cytoskeletal linker plectin, which consists
of various isoforms that facilitate interaction with IFs [42].
Plectin is highly expressed in various cell types and plays a
major role in cellular cytoskeletal organization and dynamics
[43]. Plectin interaction with nesprin-3α serves to link the
NE membrane and IFs, which in turn are linked to AFs and
MTs through members of the spectraplakin protein family
[42, 43].
Consolidation of the existing literature on subcellular
localization,proteininteractions,andlossoffunctionbehav-
ioral correlates led us to speculate that torsinA and dystonin-
a2 may both participate in protein complexes associatedInternational Journal of Cell Biology 3
with membranes of the NE/ER and the cytoskeleton. In this
paper, we present current knowledge of torsin and dystonin
proteins, including their functional similarities and diﬀer-
ences, in order to highlight common mechanisms that may
underlie diﬀerent forms of dystonia through disruption of
the link between the NE/ER and cytoskeleton that may im-
pair neuronal development and function.
2.Torsin-RelatedProteins
Torsin proteins are members of the AAA+ superfamily of
ATPases [44]. Most AAA+ proteins form oligomeric com-
plexes (typically six subunit rings) obtaining energy from
ATP hydrolysis and acting as chaperone-like modules [45].
AAA+ proteins are involved in diﬀerent cellular processes
suchas protein folding, membrane traﬃcking, vesicle fusion,
and cytoskeleton dynamics [45–47]. Other activities asso-
ciated with AAA+ proteins include peroxisome biogenesis,
assembly of mitochondrial proteins, cell cycle control, mi-
totic spindle formation, cytoskeleton interactions, vesicle-
mediated secretion, signal transduction, and transcriptional
regulation [48–51]. The AAA+ domain of torsinA contains
the Walker A motif (also known as the P-loop-ATP binding
domain), the Walker B motif (ATP hydrolysis), and the ATP
sensing motifs (sensor I and sensor II) [52, 53], and six
prominently conserved cysteine residues (Figure 1). Their
location in the lumen of the NE/ER and cysteine residues in
the AAA+ domain distinguish these torsin family members
from other AAA+ proteins [52, 54].
Two structural models of human torsinA are based
on the crystal structure of orthologues in bacteria, ClpA
[52] and ClpB [53] proteases, also members of the AAA+
ATPase superfamily that form homohexameric structures.
Both structures suggest that torsinA is composed of two
subdomains, a N-terminal α/β subdomain and a C-terminal
α-helical subdomain. The latter subdomain is the region
containing mutations in DYT1 dystonia patients [6, 10, 12].
The ΔGAG deletion associated with most cases of DYT1
dystonia removes a glutamic acid residue from an α-helix in
the C-terminal subdomain [53]. Although mutant torsinA
is presumed to be able to associate with wild-type torsinA
subunits in six subunit rings, its altered structure may serve
to decrease activity of the hexamer [55]. ATP-dependent
Clp proteases are involved in nonlysosomal removal of
damaged or misfolded proteins in bacteria [56, 57]. In mam-
maliancellsmutantormisfoldedproteinsintheERareelim-
inated by ER-associated degradation (ERAD) with torsinA
facilitating exit of proteins to the cytoplasm where they are
degraded by the ubiquitin-proteasome system [58]. Curi-
ously, ClpA/ClpB and most members of the AAA+ protein
family present a Walker A consensus GxxGxGK [T/S] motif,
which contains an essential lysine that supports binding of
nucleotides, whereas torsinA contains a noncanonical Walk-
er A sequence, GxxGxGKN [47]. When the threonine in the
Walker A motif was replaced with asparagine in the ClpB
protease, so as to make it more similar to torsinA, the ATPase
activity was partially inhibited. However, this did not aﬀect
the ability of ClpB to form hexamers. The noncanonical
Walker A sequence introduced into ClpB induced prefer-
ential binding of ADP rather than ATP and reduced its
chaperone activity invitroandinvivo[47].Thissuggeststhat
torsin proteins might utilize distinct mechanisms to couple
the ATPase cycle with their substrate-remodeling activity.
2.1.TheFourTorsinProteinsinMammals. Fourgenesencod-
ing torsin family members have been identiﬁed in mam-
mals: torsinA, torsinB (85% similar to torsinA), torsin2,
and torsin3 (67% and 61% similar to torsinA, resp.) [59]
(Figure 1). All four proteins share the core AAA+ domain
[52, 53, 60]. TorsinA and torsinB genes (TOR1Aand TOR1B,
resp.) are adjacent to each other in opposite orientations on
chromosome9q[59]).Thetorsin2gene(TOR2)islocatedon
the same chromosome in nearby region. These three torsin
genes (TOR1A, TOR1B,a n dTOR2) possess ﬁve exons. In
contrast, the torsin3 gene (TOR3) is located on chromosome
1q and has six exons. TorsinA has been the most extensively
studied due to its role in DYT1 dystonia. The glutamic
acid deletion at position 302/303 in exon 5 of torsinA is
responsible for about 80% of cases in the Ashkenazic Jewish
population and about 40% in the general population. Five
other variations have been found that change the amino acid
sequence of torsinA: F205I in exon 3 [11] with the rest in
exon 5, including R288Q [12], a 4bp deletion that causes a
frameshiftandtruncationstartingatresidue312[61],andan
18bp deletion (ΔF323−Y328) [10], but the pathogenicity of
these sequence variants has yet to be established. In addition,
there is a polymorphism in the coding sequence for residue
216 encoding aspartic acid (D) in 88% and histidine (H) in
12% of alleles in control populations [10], with the D216H
polymorphism inﬂuencing the penetrance of DYT1 dystonia
[62].
TorsinA is a 332-amino-acid protein that contains an
N-terminal ER signal sequence (SS) and a 20-amino-acid
hydrophobic region followed by a conserved AAA+ do-
main (Figure 1). The SS and glycosylation state of torsinA
are consistent with its location in the ER/NE, with the
hydrophobic N-terminal sequence apparently retaining it in
this location [13, 63–65]. However, with the exception of
torsinB, which has very similar characteristics to torsinA
[63, 66], the subcellular localization of torsin2 and torsin3
remains poorly characterized. It was recently reported that
digestion of glycosylated residues reduces the molecular
weight of all four torsins in whole-cell preparations [60],
indicating that all reside in the ER or at least pass through
that compartment and may have overlapping functions, as
do torsinA and torsinB [29].
Although torsinA is widely expressed in human tissue, it
appears to have its most critical role in the central nervous
system (CNS), where it is present at high levels during
development [67, 68]. In adult brains, high levels of torsinA
expression are found in speciﬁc neuronal populations,
such as dopaminergic neurons in the substantia nigra pars
compacta, interneurons in the striatum, and neurons in the
cerebral cortex, thalamus, hippocampus, cerebellum, mid-
brain, pons, and spinal cord [19, 69–73]. TorsinA has been
implicatedinseveralcellularpathwaysincludingNEintegrity4 International Journal of Cell Biology
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Figure 1: Schematic diagram of the AAA+ torsin protein family. The key features of torsinA, torsinB, torsin2, and torsin3 are shown,
including the signal sequence (SS; turquoise), hydrophobic domain (Hypb; grey), and AAA+ domain (purple). The AAA+ domain of
torsinA, illustrated in more detail, consists of Walker A/B (green) motifs, sensor I/II (orange) motifs, and six conserved cysteines (C). Also,
the total number of amino acids (a.a.) for each protein and the overall percentage similarity with torsinA are indicated. In torsin2, the Hydb
domain is absent and torsin3 has a longer Hydb domain. The 10a.a. region in torsinA in which the glutamic acid deletion underlying DYT1
dystonia occurs is shown in detail. Conserved a.a. residues in this region in other members of the torsin family are underlined (ﬁgure revised
from Jungwirth et al. [26] and Zhu et al. [54]).
[14–16, 24, 26, 29], cytoskeleton organization [27, 74–76],
nuclear polarity [27] (as well as the nematode homologue,
OCC-5 [77]), chaperone functions [78–82], degradation of
misfolded proteins [58, 83], ER stress sensitivity [58, 84–
87], dynamics of secretory and synaptic vesicles [88–92], and
modulation of dopamine (DA) neurotransmission [93–107].
The second most investigated torsin protein, torsinB, is
highly expressed in the lung, placenta and testis, with low
levels in the brain [29, 60, 63]. Immunoprecipitation studies
indicated that torsinA and torsinB associate with each other
[63] and have a similar distribution in nonneuronal cells [29,
60, 66]. Mutations or other pathologies in human disease
have not been reported for torsinB. Similar to torsinA,
torsinB expression is temporally and spatially regulated, with
torsinB expression in the developing brain peaking after that
of torsinA [68, 108]. The low expression of torsinB relative
to torsinA in the brain and the high expression of torsinB in
other tissues may explain why the brain is selectively aﬀected
by mutant torsinA and why nonneuronal tissue are protected
from torsinA dysfunction in DYT1 patients [29].
The other mammalian torsin members, torsin2 and
torsin3, share the core AAA+ domain and the functionally
important region aﬀected by the DYT1 mutation (Figure 1)
[52, 53]. Torsin3 contains an extended amino terminus, and
torsin2 lacks a speciﬁc Hypb between the SS and the AAA
domain (Figure 1).Todeterminewhetherothertorsinfamily
members can change their location in cells, a mutation in
the Walker B motif (E171Q, ATP-bound state) of the AAA+
domain was generated in diﬀerent members. In torsinA this
mutation leads to a substrate-trap state with defects in ATP
hydrolysis and accumulation of torsinA in the perinuclear
region [16]. Mutated Walker B motifs in torsinB (E178Q)
and torsin2 (E162Q) also led to movement out of the ER
and into the NE region, while that in torsin3 (E236Q) did
not change its location, which remained predominantly in
the ER. In contrast to other torsin family members, torsin3 is
an interferon-regulated protein [109] and may have distinct
biological function(s). Notably, three of four torsin family
members (torsinA, torsinB, and torsin2) operate within the
NE, making them candidates for involvement in nuclear-
cytoskeleton links.
2.2. TorsinA and Its Nonmammalian Orthologues. Besides
ClpA and ClpB, which are the torsinA orthologues found
in bacteria, yeast, and plants [47], other coding sequencesInternational Journal of Cell Biology 5
related to the TOR1A gene have been found in nonmam-
malian organisms, including Drosophila (Torp4a, dtorsin),
nematodes (tor-1, tor-2, and OOC-5) and zebraﬁsh (tor-
sinC) [55].
Drosophila may be a viable model for providing insights
intohumandystonia.Lossofdtorsinorexpressionofhuman
mutant torsinA, torsinAΔE, leads to abnormal motor behav-
ior in Drosophila larvae [107, 110]. Interestingly, dtorsin-
null ﬂies have decreased levels of DA and movement can
be normalized by feeding DA to larvae or by expressing
human torsinA [107]. Dtorsin is 34% identical to human
torsinA and is predominantly localized in the ER, but also
found in the NE. Although neural degeneration caused by
the loss of torsin function has not previously been reported
in other organisms, downregulation of dtorsin resulted in
increasedage-relatedretinaldegenerationinDrosophila[80].
In parallel, overexpression of dtorsin protected the retina
from degeneration.
Three torsin-like gene products are predicted in the ne-
matode Caenorhabditis elegans (C. elegans) (tor-1, tor-2, and
OOC-5). Ectopic overexpression of either tor-2 and OOC-5
or human torsinA resulted in a reduction of polyglutamine
repeat-induced protein aggregation in C. elegans, supporting
a chaperone function [94]. Moreover, mutant forms of tor-
2 were unable to ameliorate aggregation, and tor-2 and
ubiquitin colocalized at sites of protein aggregation. The
OOC-5 protein is also located in the ER/NE, and loss of
OOC-5disruptsnuclearrotationduringearlyembryogenesis
[77]. This nuclear rotation is mediated by cytoskeletal links
between the nuclear centrosome complex and the cortical
surface of the embryo [111]. In parallel, absence of torsinA
interferes with the positioning of nuclei within migrating
mouse ﬁbroblasts, thus delaying initiation of migration [27].
It has also been hypothesized that the sensor II motif in
torsin proteins (Figure 1) acts as a redox-regulated sensor.
TheoxidationofthecysteineinthesensorIImotifofOOC-5
disrupts its function [52], and, in parallel, the redox state of
this motif in torsinA inﬂuences its association with binding
partners, LAP1 and lumenal domain like LAP1(LULL1)
[54]. Both ATPase activity and protein binding to torsins
are regulated by the redox state of the ER, consistent with
their proposed role as ER chaperone proteins involved in
processing of membrane proteins and in the ER stress
response [58, 86, 88, 93].
3. Dystoninandthe Plakin Family of
CytoskeletalLinkerProteins
The eukaryotic cytoskeleton comprises three cytoskeletal
networks that include MTs, AFs, and IFs. These networks
rely upon cytoskeletal cross-linking proteins, known as pla-
kins, such as dystonin, for maintenance of their functional
integrity and interactions. Cytoskeletal linker proteins are
criticalregulatorsofcellularprocessesrangingfromvesicular
transport and maintenance of organelle integrity to mitosis
and cell death [112]. As such, impairment of cytoskeletal-
linker function impacts cell viability, development and a
variety of cellular functions and has been associated with
several organelle-speciﬁc stress pathways [41, 113, 114].
3.1. Plakins as Cytoskeletal Linkers. Members of the plakin
family of cytoskeletal proteins are critical in maintaining
the function and integrity of tissues. For example, they link
junctional complexes between cells (desmosomes and hemi-
desmosomes) with the cytoskeletal network within the cells
(for review see [114]). A common structural element con-
served in most family members is the plakin domain, com-
prising six antiparallel segments arranged in an α-helical
fashion [115]. Numerous plakin proteins have been identi-
ﬁed in mammalian central nervous system (CNS), includ-
ing dystonin (also known as bullous pemphigoid antigen
1( B P A G 1 ) )[ 8, 116], MT-actin cross-linking factor 1
(MACF1), (also known as actin-cross linking factor 7
(ACF7)) [112, 117–119], plectin (isoforms 1a, 1b, and 1c, 1e,
2a, and 3a) [112], desmoplakin and periplakin [120]. Both
plectin and desmoplakin have been demonstrated to interact
directly with IF [121]. Plectin is one of the most versatile and
ubiquitously expressed plakins. The association of plakins
with IFs changes depending on the phosphorylation state
of serine residues in the carboxy-terminal segment of the
plakin, suggesting that this interaction may be regulated
within cells [112]. Recently, it has been suggested that plectin
serves as a nucleation and assembly center for the de novo
formation of IFs networks and acts in turnover of focal
adhesions [122]. The abundance of spectrin repeats (SRs), as
found in several plakin family members, has resulted in their
further subclassiﬁcation as spectraplakins, namely, dystonin
and MACF1 (mammalian), short stop (Drosophila), and
variable abnormal morphology (VAB; C. elegans)[ 115, 123].
Mutations in plakins are associated with a variety of neuro-
logical disorders in humans [39, 124–126], while in animals
only a mutation in Dst results in a neurological phenotype.
Extensive structural homology exists among mammalian
spectraplakins,includingtheSRdomains,whichactasdock-
ingstationsforcytoskeletalelements[127],theactin-binding
domain(ABD),andMTbindingdomain(MTBD)[115,116,
118, 128, 129]. The multidomain nature of these proteins
facilitates their function in linking cytoskeletal elements
and bridging them with junctional complexes. The cellular
localization and predicted activity of dystonin implicate it
in functions of the peripheral sensory and motor nervous
system.
3.2. Dystonin Isoforms Generated by Alternative Splicing. The
Dst is a large gene (∼400kb) in mice and gives rise to three
tissue-speciﬁc dystonin protein isoforms, namely, dystonin-e
(epithelial isoform, ∼315kDa), dystonin-b (muscle isoform,
∼834kDa), and dystonin-a (neuronal isoform, ∼615kDa)
(Figure 2(a))[8,128,130,131].Dystonin-eservesasanauto-
antigen in the skin blistering disease, bullous pemphigoid
(BP) in humans and a mutation aﬀecting this isoform results
in a similar defect in mice. Loss of function of dystonin-a is
believedtobecausalindt sensory/motor neuropathy in mice
[8, 37, 131–133]. Three neuronal isoforms of dystonin-a
are generated by alternative splicing, namely, dystonin-a1,6 International Journal of Cell Biology
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Figure 2: Structural representation of dystonin protein isoforms. (a) Illustration of the modular domain structure of tissue speciﬁc dystonin
isoforms. Three tissue-speciﬁc isoforms have been identiﬁed; muscle (dystonin-b), neuronal (dystonin-a), and epithelial (dystonin-e). (b)
Dystonin-a and b isoforms vary at the N-terminus, resulting in three distinct isoforms. The isoform 1 variant possesses a sequence coding
for an ABD at the N-terminus. The isoform 2 variant contains sequence coding for a highly conserved N-terminal TM domain, while the
isoform 3 variant contains sequence coding for a conserved MYR motif.
dystonin-a2, and dystonin-a3 [134]( Figure 2(b)). These
isoforms share an ABD sequence, an extensive coiled-coil
region, and a C-terminal MTBD allowing for interactions
with actin and MTs, thus facilitating their function as cyto-
skeletal linkers [128]. They diﬀer on the basis of unique
N-terminal regions that dictate their subcellular location.
Speciﬁcally, dystonin-a1 possesses a short N-terminal do-
main that includes an ABD localizing it to AFs, dystonin-a2
possesses a transmembrane (TM) domain localizing it to the
NE and perinuclear membranes, and dystonin-a3 possesses
a putative MYR motif, aiding in anchoring it to the plasma
membrane (Figure 2(b))[ 135, 136]. The unique TM domain
of dystonin-a2 distinguishes it from other spectraplakins.
While other spectraplakins link neuroﬁlaments (NFs) to
MTs, AF or junctional complexes, dystonin-a2 links AFs
and MTs with membranes of the ER, Golgi-apparatus and
nucleus. Moreover, mutations in dystonin-a2 lead to induc-
tion of ER chaperone proteins and the unfolded protein
response, which are believed to contribute to degeneration
of both sensory and motor neurons [8, 37, 41, 137].
3.3. Dystonin Function in Neurons. Spectraplakins associate
with MTs via two conserved domains: the growth arrest-
speciﬁc 2- (Gas2-)related domain and its adjacent carboxy
terminal tail region [118, 129, 138]. While the Gas2-related
domain aligns along MT shafts and promotes MT stabiliza-
tion [129, 138], the carboxy terminus of spectraplakin family
members MACF1, and short stop bind to the MT plus-end-
binding protein 1 (EB1) and localize at growing MT ends
[139–141], establishing spectraplakins as putative plus-tip-
interacting proteins. Direct interactions between EB1 and
dystonin have not been reported, but the conserved modular
domains between dystonin-a2 and MACF1 suggest that dys-
toninmaybeinvolvedinMTpolymerization.Bothdystonin-
a2 and MACF1b have been found in the Golgi apparatus,
and overexpressed dystonin-a2 colocalizes with the cis-
Golgi protein GM130, suggesting a functional role in Golgi
apparatus-mediated MT nucleation [119, 136, 142]. Other
MT-associated proteins, such as MAP1B and clathrin, have
been shown to promote MT polymerization and stability
when localized to the Golgi apparatus [143, 144]. Dystonin-
a2 has been shown to interact with both MAP1B and
clathrin via the modular plakin domain [145]. Plus-end MT
polymerization from the Golgi apparatus toward the leading
edge of the cell supports a role in cell migration [146, 147],
and mutations in MT-associated proteins, including MAP1B
and MACF1 cause defects in neuronal migration and cortical
development [125, 148, 149]. Although no developmental
migration defects have been reported in dt neurons to date,
such deﬁcits have been noted in epithelial cells lacking the
smaller epithelial isoform (dystonin-e) [138].
Spectraplakins have also been implicated in the ultra-
structural organization of organelles. For example, the
organization of the Golgi apparatus complex is dependent
on MACF1b, which shares a similar domain structure with
neuronal dystonia-a2 [118, 119]. Chemical dispersion of
the Golgi apparatus results in redistribution of MACF1b
to the ER, while reduced levels of MACF1b induce Golgi
apparatus fragmentation. Localization of MACF1b to the
GolgiapparatusismediatedbyitsN-terminalplakindomain
[119]. This domain is conserved in dystonin-a2 and oriented
adjacent to the TM domain that positions the protein along
perinuclear membranes [41, 136]. As such, dystonin-a2
appears to be a critical modiﬁer of perikaryal structures and
may inﬂuence functions of the ER, Golgi apparatus, and
NE. Compromised organization of the ER, Golgi apparatus,
and MT network would no doubt inﬂuence protein pro-
cessingthroughthesecretorypathway.Molecularinteraction
studies have implicated dystonin in regulation of the dynein
motor complex through interaction with dynactin and the
endosomal vesicle protein, retrolinkin [150, 151]. Defective
fast axonal transport has also been reported in the sciatic
nerves of phenotypic dt27J mice in both orthograde and
retrograde directions [152]. Indeed, cytoskeletal linkers have
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organelle organization and movement in addition to sta-
bilizing the cytoskeleton. Collectively, these ﬁndings show
that functional impairment of sensory and motor neurons
can result from defects in cytoskeletal mediated intracellular
traﬃcking.
4. StudiesinHumansandMice Models with
Mutations inTOR1A andDst
4.1. Human DYT1 Dystonia: A CNS Movement Disorder.
Dystonia has been considered to be primarily a disorder of
thebasalgangliasincepatientswithsecondarydystoniacom-
monly exhibit lesions within structures associated with the
basal ganglia, including caudate, putamen, globus pallidus,
and thalamus [153–155]. However, substantial evidence also
implicates cerebellar and brainstem pathology in cases of
primary and secondary dystonia [3, 156, 157]. Hyperme-
tabolic signals within premotor cortex and cerebellum have
been found in patients with primary dystonias, including
hemidystonia, exercise-induced paroxysmal dystonia, and
DYT1 dystonia [158–161]. Symptoms of dystonia have also
been reported in familial forms of ataxia, where the degener-
ation appears to be limited to the cerebellum and brainstem
[162]. Although many interconnected brain regions can be
aﬀected in human dystonia, there does not appear to be any
pathophysiology in peripheral sensory or motor neurons.
This stands in contrast to the dt dystonic motor syndrome
in mice where the peripheral nervous system is primarily
aﬀected with marked pathology. It has been speculated that
the high expression of other members of the plakin family
in the brain, MACF1 in particular, may compensate for
dystonin loss in the CNS of dt mice [119, 125, 163].
Genetic mouse models of DYT1 dystonia have been
createdtobetterunderstandtheneurobiologicalbasisofdys-
tonia (Table 1). However, mutations that result in dystonia
in humans do not generate an obvious dystonic phenotypic
in mice. Mouse models of dystonia also do not show any
obvious evidence of neuronal loss, although in some models
the levels of striatal DA and its metabolites were reduced and
animals showed some motor abnormalities (Table 1),suchas
hyperactivity,circlingbehavior,deﬁcitsinbeamwalking,and
reducedmotorlearning[21,97,104,164,165].Somemodels
of dystonia in rats and mice implicate abnormal cerebellar
signaling, including Purkinje cells and deep cerebellar nuclei
[166–170].Inaddition,selectiveeliminationofthecerebellar
output in some mouse and rat models served to block the
dystonic symptoms [171–174].
4.2. Dystonia Musculorum: A Peripheral Nervous System
Movement Disorder in Rodents. The dt mouse arose spon-
taneously as a recessively inherited mutation with a severe
movement disorder that appeared to resemble dystonia in
humans [35]. This mouse disorder develops as a progressive
ataxia, due to the degeneration of the sensory neurons,
and appears similar to generalized dystonia with twisting
movements of the neck, paddling motions of the limbs,
and abnormal posturing of limbs and trunk. The disease
progresses rapidly and dt mice die in the third week of
life of unknown causes [8, 177]. Accumulation of NF tan-
gles within sensory neurons of dt mice is a pathological
feature of the disease [36, 179–182]. In addition, an ab-
normal accumulation of hyperphosphorylated NFs is found
in the perikarya and proximal regions of axons of spinal
motor neurons [36]. Peripheral dt pathologies have been
documented in motor neurons, skeletal muscle, and Sch-
wann cells, but degeneration is most prominent in dorsal
root ganglion sensory neurons [36, 37, 183, 184]. Inter-
estingly, dt mice also exhibit lesions within several brain
regions, including basal ganglia and cerebellum [37, 185,
186]. Several dt mouse models exist through spontaneous
mutations(dt27J,dt Alb),chemicallyinducedmutations(dt37J,
dt33J), targeted alleles (dttm1Efu), and transgenic insertions
(dtTg4)[ 130, 131]( Table 1). While only three dt mutations
(dtTg4,d t tm1Efu, and dtAlb) have been characterized at the
DNA level, dtTg4 and dt27J are allelic but do not complement
[113, 132, 137] .W h i l ei ti su n r e s o l v e da st ow h e t h e rl o s so fa
single isoform or combination of isoforms is responsible for
neuronal loss, defects in nucleoskeletal/cytoskeletal function
are paramount in these dt models.
4.3. Dystonin-Related Disorders in Humans. In humans, dys-
tonin-e was initially characterized under its pseudonym
BPAG1e as a major autoantigen in the skin blistering dis-
ease, BP [38]. In keratinocytes, dystonin-e links keratin-con-
taining IFs to hemidesmosomes [187]. Mutation of the pla-
kin family member plectin results in a similar pheno-
type in humans termed epidermolysis bullosa simplex
[188, 189]. The original characterization of dystonin-e-null
mice described similar skin defects to those observed in
humans but, unexpectedly, also showed severe neurodegen-
eration and dystonic symptoms [137]. While presentation of
dystonin-e autoantigen in humans does not result in neu-
rological deﬁcits, BP patients have been reported to have an
increased incidence of certain neurological diseases, such as
multiple sclerosis, amyotrophic lateral sclerosis, Parkinson’s
disease, Alzheimer disease, and cerebral stroke [190–197].
While the reasons behind this correlation are unknown, it
is interesting to speculate that mutations that aﬀect other
dystonin isoforms, such as dystonin-a may contribute to
neurological symptoms observed in BP patients [197]. In-
deed, in the reverse situation, an autoimmune response ini-
tially directed against neuronal dystonin-a triggered a sec-
ondary autoimmune response against dystonin-e based on
their sequence homology [198–200]. Furthermore, in one
human subject with a translocation in the human dystonin
gene (DST) that speciﬁcally disrupted dystonin-a and -b
isoforms, the patient presented with a profound delay in
cognitive and motor function, as well as visual deﬁciency
[39]. Curiously, no defect in epithelial tissue was observed,
consistent with unaltered expression of the dystonin-e iso-
form. Thus, while no mutations in DST have been identiﬁed
in humans, haploinsuﬃciency or altered expression can
result in phenotypic abnormalities with some similarities to
the inherited disorder in mice.8 International Journal of Cell Biology
Table 1: Mouse models of dystonia.
Type/mutation Anatomical phenotype Motor phenotype Reference
Dystonin/Bpag1 mutations∗
dt24J, spontaneous Nervous system Hind limb clasping, dystonia [175]
dt27J, spontaneous Nervous system Hind limb clasping, dystonia [117]
dtalb, spontaneous Behavior, nervous system, muscle Dystonia [176]
dtJ, spontaneous Mortality/aging, behavior, growth/size,
pigmentation, vision/eye,
hearing/vestibular/ear, integument
Abnormal posture, ataxia, impaired
motor coordination
[177]
dtTg4, transgenic (random gene
disruption)
Mortality/aging, behavior, nervous
system, muscle
Impaired motor coordination, hind limb
clasping
[132]
dttm1Efu, transgenic Mortality/aging, nervous system, muscle,
behavior, homeostasis, limbs/digits/tail,
integument
Dystonia [178]
DYT1 mutations†
NSE-hMT, transgenic Perinuclear aggregates stained for torsinA
and ubiquitin
Hind limb clasping, marked
hyperactivity, circling
[21]
CMV-hMT, transgenic Not reported Limited improvement on repeated
rotarod testing in old animal
[165]
Prion-hMT, transgenic Perinuclear aggregates stained for torsinA
and ubiquitin
Limited improvement on repeated
rotarod testing in old animals
[164]
torsinA knock-in, heterozygous Perinuclear aggregates stained for torsinA
and ubiquitin, NE abnormalities in
neurons
Mild hyperactivity, poor performance on
beam walking test
[23]
torsinA knock-out, heterozygous Peduced amount of torsinA; NE
abnormalities in neurons
Similar to knock-in(heterozygous) [96]
Cortex-speciﬁc torsinA knock-out,
heterozygous
Not reported Deﬁciency on beam-walking test,
hyperactivity
[98]
TH- hMT, transgenic Not reported Similar to CMV-hMT, transgenic [104]
NSE: neuron-speciﬁc enolase promoter; CMV: cytomegalovirus promoter; hMT: human torsinA mutant; hWT: human torsinA wild type; NE: nuclear
envelope; TH: tyrosine hydroxylase.
∗Based on information retrieved from the International Mouse Genome Database (MGI)
†Adapted from Jinnah et al. [169].
5. SimilaritiesbetweenCellularFunctions of
TorsinAandDystonin-a2
5.1. Link between NE/ER and Cytoskeleton. Mutations in
both mouse Dst and human TOR1A genes result in aber-
rations of NE/ER morphology. The homozygous knock-out
and knock-in torsinAΔE mouse models of DYT1 dystonia
show abnormalities in structure of the NE in embryos,
largely conﬁned to CNS neurons [25]. dt mice also manifest
nuclear eccentricity and loss of chromophilic material from
around the nucleus in neurons in the red nucleus of
the rostral midbrain and discrete regions of the striatum,
likely due to perinuclear swelling and disorganization of
the rough ER [35, 41, 179, 185, 201]. Nuclear eccentricity
has been reported for several dt alleles and correlates with
disease onset [37, 41]. Furthermore, mutation in dystonin-
a2 results in accumulation of AFs around the nucleus and
Golgi apparatus [136], which is in line with human DYT1
ﬁbroblast in which has been shown nuclear accumulation of
IF protein, vimentin [75].
In addition, torsinA and dystonin proteins have been
attributed with roles in ER organization and ER stress.
Overexpression of wild-type torsinA has no marked eﬀect
on its ER distribution as compared with endogenous levels
of torsinA, showing the typical reticular pattern throughout
the cell body. In contrast, torsinAΔE overexpression causes
torsinA immunoreactivity to accumulate in the NE region
[13, 15, 16]. Furthermore, overexpression of a truncated
form of torsinA (torsinA313-332) initiates changes in ER
macrostructure, resulting in a vacuolar distribution of both
torsinA and protein disulﬁde isomerase (PDI) [58]. No
TM proteins in the ER have been identiﬁed that interact
with both torsinA and the cytoskeleton. However, protein
processing in the ER depends on dynamic movement of
membranes mediated by the cytoskeleton, especially in
neurons [202]. While an association between torsinA and
dystonin has not been demonstrated, the TM domain of
dystonin-a2 makes it an interesting candidate in this respect.
Both proteins localize to the ER and NE and associate
with nesprin-3α, as well as inﬂuence the structure of the
NE and ER membranes, suggesting that these two proteins
participate in common functional pathways.
Studies in dtTg4 mice have implicated mutations in Dst
with ER-stress induction, based on upregulation of proteinInternational Journal of Cell Biology 9
chaperones, PDI and binding immunoglobulin protein
(BiP),alsoknownas78kDaglucose-regulatedprotein(GRP-
78) upon phenotypic onset of dystonia [41]. This suggests
the possibility that disruption in the link between the ER
and the cytoskeleton may initiate a proapoptotic signalling
cascadeinneuronsofdt miceinitiatedbyERstress.Similarly,
torsinA-deﬁcient mouse embryonic ﬁbroblasts (MEFs) have
increased ER stress, as compared to torsinA wild-type
MEFs as detected by elevated BiP levels [87]. Furthermore,
DYT1 ﬁbroblasts elicit an ER stress response at lower
concentrations of stress-inducing drugs as compared to
ﬁbroblasts from controls, and wild-type torsinA can reduce
ER stress caused by ER protein overload in nematodes [58].
Recently, torsinA was found to coimmunoprecipitate with
ERAD components, including Derlin-1, p97, and VIMP
(VCP-interacting membrane protein), and downregulation
of torsinA or expression of mutant torsinA compromised the
cell’s ability to eliminate mutant proteins from the ER [58].
Interestingly, torsinA and p97 have been found in inclusion
bodies in brain and peripheral nerves of patients with a
variety of neurodegenerative diseases, as well as dystonia
suggesting their involvement in elimination or sequestration
oftoxicproteins[203–206].ConsistentwithtorsinAfunction
in ERAD, it has also been found to be involved in quality
control of ε-sarcoglycan (SGCE) processing [83], with SGCE
expressed at high levels in the brain [207] and mutated
in human myoclonic dystonia [208]. The involvement of
torsinA in the ERAD pathway may help to explain the
increased sensitivity of cells to ER stress following loss of or
mutation in torsinA, with ER stress possibly contributing to
onset of dystonia in DYT1 carriers [58, 86].
5.2.Nesprin-3α:ACommonAssociatedPartnerofDystonin-a2
and TorsinA. Nesprin proteins are evolutionarily conserved
nuclear TM proteins that couple the NE with the cytoplas-
mic cytoskeleton (directly to MTs and AF and indirectly
through plakins to IFs) [209]. Nesprin proteins possess a
conserved 50 to 60 residue C-terminal KASH (Klarsicht,
Anc-1, Syne Homology) domain featuring a single TM
segment followed by a short lumenal sequence. To date
four nesprin proteins have been identiﬁed [210]: nesprin-
1 (also known as Syne1, Myne-1, and Enaptin), nesprin-2
(also known as Syne2, Myne-2, and NUANCE), nesprin-3
andnesprin-4.Fornesprins-1and-2,theprimarytranscripts
encode several alternatively spliced isoforms [170]. The
largest of these, nesprin-1 Giant (Nesp1G; 1,000kDa) as
well as nesprin-2 Giant (Nesp2G; 800kDa), reside in the
ONM. Smaller isoforms may be found in the INM [211,
212]. The large ﬂexible cytoplasmic domains of Nesp1G
and Nesp2G each feature an N-terminal ABD followed by
multiple SRs. Nesp1G and Nesp2G localize to the ONM via
their KASH domain, which binds in the NE lumen to the
INM domain of SUN proteins. These nesprins are able to
form a link to the actin cytoskeleton through their calponin
homology domains [31, 213]. Nesprins are anchored in a
similar way as SUN proteins but nesprin-3 interacts with
IFs in the cytoplasm by binding to plectin [42]. Unlike
nesprin-1 and -2, nesprin-3 lacks an ABD domain and is
NE
SUN
Intermediate
ﬁlaments
Plectin
Cytoplasm
Laminin
Nesprin-3α
Microtubules
Dystonin-a2
TM domain
KASH domain
Nucleus
IFBD
MTBD
A
B
D
A
B
D
TorsinA
Figure 3: Hypothesized model for torsinA, dystonin-a2, and their
common associated partner, nesprin-3α. This schematic represents
the associations between torsinA and dystonin-a2 with nesprin-3α,
a type II TM protein in the ONM that contains a C-terminal KASH
domain within the lumenal space of the NE. Nesprin-3α interacts
with SUN proteins (green and gray), which span the INM of the
NE, through its KASH domain (purple). TorsinA (red hexameric
circles) associates with nesprin-3α and regulates its interaction with
SUN proteins. The N-terminus of nesprin-3α binds to the plakin
family member, plectin, which in turn links to IFs through its IF-
binding domain (IFBD; blue). Dystonin-a2 has a TM domain (dark
blue) at the N-terminus, which embeds in the ONM of the NE and
associates with nesprin-3α. Like plectin, dystonin-a isoforms are
members of the plakin protein family and are characterized by SR
domains indicated by the “chain shape” (gray) and an ABD (pink)
in the N-terminal region. The dystonin-a2 isoform also possesses a
C-terminal MTBD through which it associates with microtubules.
Collectively, these proteins function to bridge the NE and ER with
the three major cytoskeleton networks present in eukaryotes.
therefore unable to associate with actin directly, but forms an
interconnected mesh with AFs, MTs, and IFs through plakin
familymembers,plectinisoforms,anddystonin-a2[43,214–
216], but it is unclear yet which isoform(s) is involved.
Nesprin-3 has two splice variants, nesprin-3α and nesprin-
3β. Only nesprin-3α contains an N-terminal binding site for
plectin that provides a bridge to IF cytoskeletal elements via
C-terminal of plectins (Figure 3)[ 42]. Nesprin-4 has been
identiﬁed as a kinesin-1-binding protein in the NE [210]
and nesprin-1 binds kinesin-2, mediating the transport of
membranes to the midbody of cells undergoing cytokinesis
[217]. These ﬁndings suggest that other nesprins at the NE
may also bind kinesins. Interestingly, nesprin-4 expression
seems to be restricted mainly to secretory epithelia, where10 International Journal of Cell Biology
it may inﬂuence centrosome/nuclear positioning and the
relationship of the Golgi apparatus to the nucleus [210].
Proteins linking the NE and cytoskeleton have been
the subject of many investigations (for reviews see [218,
219]). TorsinA has been shown to associate with a nesprin-
3, plectin, and vimentin complex through its interaction
with the KASH domain of nesprin [27]. The C-terminus of
torsinA also associates with the KASH domain of nesprin-1
and nesprin-2. In the absence of torsinA, nesprin-3 moves
away from the nucleus into the ER [27]. Also, in DYT1
patient ﬁbroblasts nesprin-3 accumulates in globular struc-
tures, presumably derived from the NE/ER, suggesting that
mutant torsinA interferes with the interaction of nesprin-
3 with its binding partners in the NE [27]. We propose
that both dystonin and torsinA inﬂuence the interaction
between the NE and cytoskeleton through their association
with nesprins in the ONM (Figure 3).
The association between dystonin-a2 and nesprin-3α
highlights their role in linking the NE/ER to the cytoskeleton
(Figure 3). The common modular structure between plectin
isoforms and dystonin-a implicates the ABD as a critical
mediator of interactions between multiple proteins and
nesprin-3α. Two-hybrid analysis revealed that the ABD
of dystonin-a facilitates interaction with nesprin-3α [42].
Furthermore, studies have elucidated the dystonin isoforms
involved in this interaction, with dystonin-a2 (ABD and
TM), but not isoform a3 (ABD only), being coimmuno-
precipitated with nesprin-3α [41]. This association was
attributed to the TM domain adjacent to the ABD at the N-
terminus of dystonin-a2 that uniquely positions the protein
near perikaryal membranes.
6. Conclusions
TorsinA and dystonin-a2 share many features, including
causing neurologic diseases with a dystonic phenotype when
mutated in humans and mice, respectively, with the onset
of symptoms occurring at a young age. Although DYT1
dystonia is inherited as an autosomal dominant disease and
dt dystonia in mice as an autosomal recessive disease, both
represent a decrease or loss of function, respectively, of the
normal wild-type protein. Both proteins are associated with
the NE and ER. While torsinA remains in the contiguous
lumensharedbytheNEandER,dystonin-a2isacytoplasmic
protein associated with NE/ER, as well as Golgi membranes.
Both torsinA and dystonin-a2 have been found to be asso-
ciated with nesprin-3α, which forms a link between the
ONM of the NE and the cytoskeleton, with mutated ver-
sions of both proteins causing abnormal morphology of
the NE and formation of perinuclear inclusions involving
cytoskeletal proteins. Loss of function of both proteins is
associated with increased sensitivity to ER stress, which can
cause cellular dysfunction and/or lead to neuronal apoptosis.
TorsinA and dystonin-a2 are both critical to neuronal
functions, albeit in diﬀerent neuronal subpopulations. Al-
though DYT1 dystonia is primarily a disease of the brain
without marked neurodegeneration and dt dystonia aﬀects
primarily peripheral sensory and motor neurons with neu-
rodegeneration, there is evidence that some areas of the
brain are also aﬀected by Dst mutations. A distinct diﬀerence
between diseases caused by mutations in these two proteins
is the early death of dt mice, while DYT1 patients have
few, if any, other medical problems related to their dystonia.
Both proteins have been implicated in a variety of cellular
processes,includingprocessingofproteinsthroughsecretory
pathways, transport of organelles along neuronal processes,
and cell migration. Their broad involvement in cellular
mechanisms can be explained by their interaction with the
cytoskeleton, which is critical in many cellular processes.
Thus, dystonin-a2 and torsinA share similar functions, and
the reason they aﬀect diﬀerent neuronal populations pre-
sumably reﬂects their diﬀerential expression in speciﬁc neu-
ronal subtypes. Dystonin-a2 is primarily expressed in sen-
sory and motor neurons in the peripheral nervous system,
whereas torsinA is mainly expressed in speciﬁc neurons in
the CNS. Understanding their common functions supports
the critical role of NE/ER cytoskeletal interactions in main-
taining neuronal integrity and function, with dysfunction at
many levels of the nervous system contributing to abnormal
dystonic movements.
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